Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) CEO Marc D. Beer purchased 10,000 shares of the stock on the open market in a transaction dated Tuesday, June 3rd. The stock was purchased at an average cost of $30.12 per share, with a total value of $301,200.00. Following the purchase, the chief executive officer now directly owns 69,400 shares in the company, valued at approximately $2,090,328. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) net profit margin is -82.20% and weekly performance is 3.68%. On last trading day company shares ended up $34.06. Analysts mean target price for the company is $71.36. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) distance from 50-day simple moving average (SMA50) is -12.67%.
Seattle Genetics Inc. (NASDAQ:SGEN) Director Felix Baker purchased 281,963 shares of Seattle Genetics stock in a transaction dated Wednesday, June 4th. The shares were purchased at an average cost of $34.86 per share, with a total value of $9,829,230.18. Following the acquisition, the director now directly owns 76,997 shares in the company, valued at approximately $2,684,115. Seattle Genetics, Inc. (NASDAQ:SGEN) shares fell -0.35% in last trading session and ended the day on $37.46. SGEN gross Margin is 91.70% and its return on assets is -13.10%.Seattle Genetics, Inc. (NASDAQ:SGEN) quarterly performance is -27.66%.
Coronado Biosciences Inc (NASDAQ:CNDO) CFO Lucy Lu bought 5,000 shares of Coronado Biosciences Inc stock in a transaction dated Monday, June 2nd . The shares were purchased at an average price of $ 1.37 per share, with a total value of $ 6,850.00. Coronado Biosciences Inc. (NASDAQ:CNDO) shares moved up 0.59% in last trading session and was closed at $1.71, while trading in range of $1.67 – $1.71. Coronado Biosciences Inc. (NASDAQ:CNDO) year to date (YTD) performance is -34.98%.
Heat Biologics Inc. (NASDAQ:HTBX) Chief Executive Officer Jeff A. Wolf, MBA bought 346 shares in a transaction dated Monday, 19 may. The shares were purchased at an average price of $4.1 per share, with a total value of $1418. Heat Biologics Inc. (NASDAQ:HTBX) ended the last trading day at $4.27. Company weekly volatility is calculated as 6.58% and price to cash ratio as 1.17.Heat Biologics Inc. (NASDAQ:HTBX) showed a negative weekly performance of -11.41%.